Potentiation of tumour necrosis factor-mediated cell killing by VP16 on human ovarian cancer cell lines. In vitro results and clinical implications
- 31 December 1993
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 29 (8) , 1157-1161
- https://doi.org/10.1016/s0959-8049(05)80307-7
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Potentiation by Tumor Necrosis Factor of Mitoxantrone Cytotoxicity to Human Ovarian Cancer Cell LinesJapanese Journal of Cancer Research, 1992
- Synergistic cytotoxic effects of recombinant human tumor necrosis factor and Etoposide (VP16) or Doxorubicin on A2774 human epithelial ovarian cancer cell lineInternational Journal of Gynecologic Cancer, 1992
- Effect of recombinant human tumor necrosis factor on A2774 human ovarian cancer cell line: Potentiation of mitoxantrone cytotoxicityGynecologic Oncology, 1991
- Tumour necrosis factor as an anticancer agentEuropean Journal of Cancer and Clinical Oncology, 1990
- Tumor Necrosis Factor and Disease Severity in Children with Falciparum MalariaNew England Journal of Medicine, 1989
- TUMOUR NECROSIS FACTOR ACTIVITY IN JOINT FLUIDS FROM RHEUMATOID ARTHRITIS PATIENTSRheumatology, 1989
- Increased tumor necrosis factor production by monocytes in alcoholic hepatitisHepatology, 1989
- ARDS, Neutrophils, and PentoxifyllineAmerican Review of Respiratory Disease, 1988
- Bone-Resorbing Agents Affect the Production and Distribution of Procollagenase as well as the Activity of Collagenase in Bone Tissue*Endocrinology, 1988
- Macrophage-induced angiogenesis is mediated by tumour necrosis factor-αNature, 1987